Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report From The Business Research Company Covers Trends, Segments And Forecasts
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The viral genome sequencing market size has experienced rapid expansion in recent years. Its value is projected to increase from $6.71 billion in 2025 to $7.72 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.9%. This historical growth can be linked to several factors, including the increasing prevalence of viral outbreaks, the uptake of next-generation sequencing, the expansion of clinical diagnostics, government financial support for research, and the demand for epidemiological studies.
The viral genome sequencing market is anticipated to see considerable expansion over the next few years. It is projected to increase to $13.57 billion by 2030, achieving a compound annual growth rate (CAGR) of 15.1%. This growth during the forecast period can be attributed to elements such as AI-driven genome analysis, the expansion of vaccine development programs, the adoption of portable sequencing technologies, integration with predictive bioinformatics, and a heightened focus on real-time pathogen monitoring. Key trends expected in the forecast period include high-throughput viral genome sequencing, portable sequencing devices, integration with bioinformatics platforms, automated sample processing, and real-time mutation tracking.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=55654252&type=smp
What Major Growth Factors Are Impacting The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?
The escalating prevalence of urological cancers is expected to drive the growth of the urine tumor deoxyribonucleic acid (DNA) testing market in the coming years. Urological cancers, which affect the urinary system and male reproductive organs including the kidneys, bladder, prostate, and testes, are increasing in incidence largely due to aging populations, as the risk of cancer rises with advancing age. Urine tumor DNA testing plays a vital role in managing these cancers by facilitating the non-invasive detection of cancer-specific genetic mutations in urine, thereby enabling early diagnosis, effective disease monitoring, and personalized treatment planning. For instance, in December 2025, Cancer Australia, an Australia-based government department, estimated that 28,868 new prostate cancer cases would be diagnosed, representing approximately 30% of all new cancer diagnoses among men. Therefore, the increasing prevalence of urological cancers is anticipated to fuel the expansion of the urine tumor deoxyribonucleic acid (DNA) testing market.
What Key Segment Areas Are Included In The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Assessment?
The urine tumor deoxyribonucleic acid (DNA) testing market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction-based, Next-Generation Sequencing, Other technologies
2) By Product Type: Assay Kits, Instruments, Services
3) By Cancer Type: Bladder Cancer, Prostate Cancer, Kidney Cancer, Other Cancer Types
4) By Sample Type: First-Morning Urine, Random Urine Samples, Catheterized Urine Samples
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction
2) By Next Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing
3) By Other Technologies: Microarray Based Testing, Hybridization Based Assays, Mass Spectrometry Based Analysis, Fluorescence In Situ Hybridization
Which Trends Are Influencing The Expansion Of The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?
Companies active in the urine tumor deoxyribonucleic acid (DNA) testing market are intensifying their efforts to create cutting-edge solutions, notably urine-based liquid biopsy platforms, which aim to allow non-invasive cancer detection, enhance diagnostic precision, and facilitate individualized treatment strategies. These urine-based liquid biopsy platforms represent non-invasive diagnostic tools engineered to identify and examine tumor-derived DNA and various other biomarkers found in urine specimens, serving purposes such as cancer detection, surveillance, and evaluation of disease advancement. As an illustration, in September 2024, PreAnalytiX, a collaborative entity formed by QIAGEN, a Netherlands-based sample-to-insight provider, and Becton, Dickinson and Company, a US-based medical technology firm, unveiled a groundbreaking urine-based liquid biopsy offering specifically designed for superior DNA stabilization and extraction, essential for subsequent molecular analyses. This platform, developed for both clinical and research contexts, incorporates features like consistent urine collection, effective DNA preservation, and seamless integration with next-generation sequencing processes, thereby promoting prompt cancer identification, accurate biomarker evaluation, and enhanced patient care.
Who Are The Prominent Players Across The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?
Major companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Illumina Inc., QIAGEN N.V., Bio-Techne Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., MDxHealth SA, Biodesix Inc., Sysmex Inostics GmbH, Pacific Edge Limited, Apostle Inc., Lucence Diagnostics, Pangea Laboratory, Nucleix Ltd, Genomica Lab, Vesica Health, Biocept Inc., Promis Diagnostics Inc.
Access The Complete Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report:
Which Area Represents The Largest Portion Of The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?
North America was the largest region in the urine tumor deoxyribonucleic acid (DNA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urine tumor deoxyribonucleic acid (DNA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample_request?id=55654252&type=smp
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
